Kidney Cancer Clinical Trials

55 recruiting

Kidney Cancer Trials at a Glance

70 actively recruiting trials for kidney cancer are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Not Applicable with 19 trials, with the heaviest enrollment activity in Bethesda, Lyon, and Tours. Lead sponsors running kidney cancer studies include National Cancer Institute (NCI), Gustave Roussy, Cancer Campus, Grand Paris, and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Browse kidney cancer trials by phase

Treatments under study

About Kidney Cancer Clinical Trials

Looking for clinical trials for Kidney Cancer? There are currently 55 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Kidney Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Kidney Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 70 trials

Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Bladder CancerKidney CancerRenal Cancer+2 more
National Cancer Institute (NCI)5,950 enrolled1 locationNCT00026884
Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Not Applicable

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Melanoma (Skin Cancer)Renal Cell Carcinoma (Kidney Cancer)Breast Cancer (Triple Negative Breast Cancer (TNBC))
Jessica Mezzanotte Sharpe25 enrolled1 locationNCT07555210
Recruiting

Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

Kidney CancerKidney NeoplasmsPneumothorax+1 more
National Cancer Institute (NCI)950 enrolled1 locationNCT00033137
Recruiting

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

Kidney CancerRenal Tumor HistologyCutaneous Leiomyoma
National Cancer Institute (NCI)1,130 enrolled1 locationNCT00050752
Recruiting
Not Applicable

Rein 3D PRINT MECHANICS

Kidney Cancer
University Hospital, Bordeaux50 enrolled1 locationNCT06525831
Recruiting

Validation of RCC Predicting Model With Emulated-target Trial

Prognostic Cancer ModelRenal Cell Carcinoma (RCC)Prognosis+4 more
Peking University Third Hospital4,700 enrolled1 locationNCT07117227
Recruiting
Phase 2

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

Renal Cell CarcinomaKidney CancerRenal Cancer+1 more
University of Colorado, Denver17 enrolled3 locationsNCT05969496
Recruiting
Phase 1

A Study of VET3-TGI in Patients With Solid Tumors

Cervical CancerNon-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma+10 more
KaliVir Immunotherapeutics60 enrolled7 locationsNCT06444815
Recruiting
Phase 1

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

Kidney CancerPhase 1bHC-7366+1 more
M.D. Anderson Cancer Center35 enrolled1 locationNCT07401875
Recruiting

Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer

Renal Cell Carcinoma (Kidney Cancer)Fear of Cancer Recurrence
Brigitta Rasmussen Villumsen105 enrolled3 locationsNCT07234656
Recruiting

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

Renal Cell CarcinomaKidney CancerClear Cell Renal Cancer+2 more
National Cancer Institute (NCI)5,000 enrolled1 locationNCT00001238
Recruiting

Study of Post-operative Complications After Laparoscopic Outpatient Nephrectomy

Kidney Cancer
GCS Ramsay Santé pour l'Enseignement et la Recherche50 enrolled1 locationNCT06532422
Recruiting
Phase 3

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Cancer (ccRCC)Renal Cell Carcinoma (Kidney Cancer)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited40 enrolled5 locationsNCT07197580
Recruiting
Not Applicable

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

Risk of Breast CancerRisk of Gynaecological CancerRisk of Colorectal Cancer+14 more
Gustave Roussy, Cancer Campus, Grand Paris5,909 enrolled1 locationNCT06907095
Recruiting
Phase 2

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

Metastatic Renal Cell CarcinomaRenal Cell CarcinomaKidney Cancer+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins20 enrolled1 locationNCT03786796
Recruiting
Phase 2

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Metastatic Renal Cell CarcinomaRenal Cell CarcinomaKidney Cancer+3 more
Stephanie Berg25 enrolled2 locationsNCT07123090
Recruiting
Phase 2

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Renal Cell CarcinomaKidney CancerRenal Carcinoma+1 more
Dana-Farber Cancer Institute32 enrolled3 locationsNCT07397611
Recruiting
Not Applicable

Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy

Kidney Cancer
Institut Paoli-Calmettes60 enrolled1 locationNCT06882486
Recruiting

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Renal Cell Carcinoma (Kidney Cancer)
Daniel Keizman300 enrolled1 locationNCT07485114